FDA Measures Naloxone Price Trend In Considering Wider Availability
This article was originally published in The Tan Sheet
Even though FDA cannot consider drug pricing, it gives research of naloxone sales to inform workshop on uptake and use. Amphastar’s naloxone prices are being scrutinized by state officials and a House member.
Register for our free email digests: